Related Experiment Videos
Increase in dendritic cell numbers, their function and the proportion uninfected during AZT therapy
M Gompels1, S Patterson, M S Roberts
1Antigen Presentation Research Group, Imperial College School of Medicine, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK.
Clinical and Experimental Immunology
|July 2, 1998
Summary
Azidothymidine (AZT) treatment boosts numbers and function of dendritic cells (DC) in HIV patients. This improves immune response by reducing viral load within DC, indicating AZT
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Human Immunodeficiency Virus (HIV) infection severely impacts peripheral blood dendritic cells (DC), crucial immune cells.
- Dendritic cells play a vital role in initiating adaptive immune responses, particularly T cell proliferation.
- Understanding the effects of antiretroviral therapy on DC function is critical for managing HIV-associated immunodeficiency.
Purpose of the Study:
- To investigate the impact of Azidothymidine (AZT) treatment on the quantity, infection level, and function of peripheral blood dendritic cells (DC) in HIV-infected patients.
- To assess changes in DC numbers and their capacity to stimulate T cells during AZT therapy.
- To evaluate the correlation between AZT treatment duration and improvements in DC characteristics and viral load reduction.
Main Methods:
- A cross-sectional study design was employed, comparing HIV patients before and up to 20 months after initiating AZT treatment.
- Peripheral blood dendritic cells (DC) were isolated using density gradient centrifugation.
- DC numbers, proviral DNA load (per provirus copy), and allogeneic T cell proliferation capacity were measured.
Main Results:
- Dendritic cell (DC) numbers, initially below normal range, increased significantly between 3 and 12 months of AZT treatment.
- The number of DC per provirus copy increased substantially, indicating a significant reduction in viral load within DC from 3 to 20 months.
- The capacity of DC to stimulate T cell proliferation, initially impaired, showed significant improvement between 6 and 12 months post-AZT initiation.
Conclusions:
- Azidothymidine (AZT) treatment demonstrates beneficial effects on dendritic cells (DC) in HIV patients, enhancing their numbers and function.
- AZT therapy effectively reduces viral load within DC and improves their ability to stimulate T cell responses.
- The positive impact of AZT on DC function supports their importance in HIV pathogenesis and suggests AZT's therapeutic efficacy can be monitored through DC status.